| Symbol | HELP |
|---|---|
| Name | CYBIN INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 100 KING STREET WEST,SUITE 5600, TORONTO, M5X 1C9, Canada |
| Telephone | +1 908 764-8385 |
| Fax | — |
| — | |
| Website | https://www.helus.com/ |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001833141 |
| Description | Cybin is focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders, all protected under its ever-growing IP portfolio. Additional info from NASDAQ: |
Helus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in Boston
Read moreA Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening
Read moreHelus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
Read moreHelus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results
Read moreNew Form 40-F - CYBIN INC. <b>Filed:</b> 2026-06-29 <b>AccNo:</b> 0001833141-26-000046 <b>Size:</b> 12 MB
Read moreHelus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress
Read moreHelus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference
Read more